<DOC>
	<DOCNO>NCT00374205</DOCNO>
	<brief_summary>The purpose study compare effectiveness safety two Artemisinin Combination Therapies ( ACTs ) treatment child uncomplicated Plasmodium falciparum malaria</brief_summary>
	<brief_title>Randomized Trial Effectiveness ACTs Ghana</brief_title>
	<detailed_description>Childhood mortality relate Plasmodium falciparum malaria rise 1 million death per year Sub-Saharan Africa . In context grow drug-resistance antimalarial health official call rapid replacement fail drug combine antimalarial drug . Artemisinin Combination Antimalarial Therapies ( ACTs ) focus malaria control program recommended first-line treatment African country . ACTs report highly effective artemisinin derivative cause rapid substantial decrease parasite load use treat patient malaria resistance artemisinin still lack . However , short half-lives artemisinins result frequent recrudescent infection use alone therefore , much interest lay choice combination partner drug . ACTs also propose mean reduce transmission reduction gametocytes delay spread drug resistance prolong therapeutic life span . Nevertheless , drug resistance parasite respective partner drug matter concern . Artesunate-amodiaquine ( AQ ) artemether-lumefantrine ( AL ) two register fixed-dose artemisinin combination chemotherapy use Africa GMP-manufactured industrial scale . There still limit data randomise , control trial support general effectiveness two ACTs Africa , include Ghana . More data need compare two therapy make evidence-based first-line treatment decision . Importantly , difficult predict combination therapy may affect spread drug resistance monitor drug resistance marker embed trial guide drug policy decision . The aim open-labelled , randomised drug trial compare effectiveness safety artesunate-amodiaquine ( Arsucam® ) artemether plus lumefantrine ( Coartem® ) treatment child five year age uncomplicated Plasmodium falciparum malaria .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>Male female outpatient age 6 month 59 month Absence severe malnutrition A slideconfirmed P. falciparum asexual parasitaemia 2,000/µl 200,000/µl A measure axillary temperature ≥ 37.5 °C rectal/tympanic temperature ≥ 38.0 °C Absence general danger sign ( unable drink ; repeat vomiting ; recent history convulsion ; lethargic unconscious state ; unable stand sit ) Ability tolerate oral therapy Permanent residence study area Informed consent legal representative subject , possible , parent Adequate antimalarial treatment within previous 7 day Antibiotic treatment current infection Previous participation clinical trial Haemoglobin &lt; 5 g/dl Leucocyte count : &gt; 15000/µl Mixed plasmodial infection Severe malaria define WHO recommendations Any severe underlying disease ( cardiac , renal , hepatic disease , malnutrition , know HIV infection ) concomitant disease mask assessment response History allergy intolerance trial medication</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Ghana</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Safety</keyword>
	<keyword>Drug-Resistance</keyword>
	<keyword>ACT</keyword>
	<keyword>Coartem</keyword>
	<keyword>Arsucam</keyword>
</DOC>